Vanguard Group’s Nuvectis Pharma NVCT Stock Holding History

Vanguard Group’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$6.38M	Buy	845,502 +146,794	+21%	+$957K	﹤0.01%	3165
2025 Q3	$4.21M	Buy	698,708 +31,903	+5%	+$219K	﹤0.01%	3332
2025 Q2	$4.98M	Buy	666,805 +199,386	+43%	+$1.81M	﹤0.01%	3221
2025 Q1	$4.57M	Buy	467,419 +142,122	+44%	+$1.02M	﹤0.01%	3212
2024 Q4	$1.76M	Buy	325,297 +24,159	+8%	+$151K	﹤0.01%	3605
2024 Q3	$1.89M	Buy	301,138 +50,000	+20%	+$329K	﹤0.01%	3573
2024 Q2	$1.59M	Sell	251,138 -47,662	-16%	-$324K	﹤0.01%	3635
2024 Q1	$2.45M	Buy	298,800 +4,517	+2%	+$38.4K	﹤0.01%	3525
2023 Q4	$2.45M	Buy	294,283 +3,149	+1%	+$28.1K	﹤0.01%	3532
2023 Q3	$3.75M	Buy	291,134 +25,196	+9%	+$365K	﹤0.01%	3363
2023 Q2	$4.25M	Buy	265,938 +64,505	+32%	+$1.03M	﹤0.01%	3383
2023 Q1	$2.64M	Buy	201,433 +5,604	+3%	+$56.8K	﹤0.01%	3576
2022 Q4	$1.47M	Buy	195,829 +168,768	+624%	+$1.21M	﹤0.01%	3781
2022 Q3	$192K	Buy	27,061 +3,804	+16%	+$35.4K	﹤0.01%	4426
2022 Q2	$261K	Buy	+23,257	New	+$288K	﹤0.01%	4431

Other funds holding NVCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Vanguard Group's NVCT Position: Q4 2025 in Review

Vanguard Group increased its Nuvectis Pharma (NVCT) stake by 21% in Q4 2025, buying an estimated $957K and bringing the position to 845,502 shares worth $6.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3165.

Vanguard Group first reported a position in NVCT in Q2 2022 and has held it in 15 quarters since. 48 funds tracked by Wall St. Rank hold NVCT as of Q4 2025.

Vanguard Group held 845,502 shares of Nuvectis Pharma worth $6.38M as of Q4 2025.
Vanguard Group bought 146,794 Nuvectis Pharma shares in Q4 2025, an estimated $957K.
Nuvectis Pharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3165 holding.
Vanguard Group first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 15 quarters since.
48 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.